AHK-Cu (Copper Tripeptide-3)
Copper Tripeptide-3; Ala-His-Lys-Cu; L-alanyl-L-histidyl-L-lysine copper(II); AHK copper peptide
The Ground Truth Score
four plain questions, never one numberLab-promising, human-unproven copper peptide for hair
Bottom line
AHK-Cu has one credible in-vitro/ex-vivo study suggesting it nudges hair-follicle biology, but no controlled human trial has ever tested whether it actually grows hair on a person.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓No established human dose.
Reported, not prescribed. Verify your vial and your math.
First documented human use
No controlled human (in vivo) trial completed as of June 2026. The only primary research, Pyo et al. 2007 (Arch Pharm Res), used explanted human hair follicles in culture and cultured dermal papilla cells, laboratory tissue, not living subjects. AHK-Cu is sold and self-applied topically in cosmetic scalp serums, but that uncontrolled consumer use is not a trial.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- A copper-bound tripeptide (alanine-histidine-lysine) marketed as a hair-specific cousin of the better-known skin peptide GHK-Cu, the alanine swap is pitched as making it preferentially active in the follicle.
- In cultured cells and explanted human follicles it made dermal papilla cells proliferate, resist apoptosis, raise VEGF (proposed to boost follicle blood supply) and lower TGF-beta1 (a catagen/regression signal), a mechanistically attractive 'extend the growth phase' story.
- Topical, peptide-based, and low-dose, so it is positioned as a gentle, side-effect-light add-on or alternative to minoxidil/finasteride for people who want a 'natural' regimen.
- Cheap to formulate and already blended into many over-the-counter copper-peptide scalp serums (often stacked with GHK-Cu), making it easy to obtain and try.
The data behind each bullet
What actually backs it
AHK-Cu (10^-12 to 10^-9 M) stimulated elongation of human hair follicles ex vivo and proliferation of dermal papilla cells in vitro.
Single in-vitro/ex-vivo study (Pyo et al. 2007, Arch Pharm Res); explanted follicles and cultured cells, not living humans. Higher concentrations (10^-8 to 10^-7 M) inhibited growth.
PubMed: Pyo 2007, tripeptide-copper complex on human hair growth in vitro (PMID 17703734) ↗AHK-Cu raised dermal-fibroblast VEGF and lowered TGF-beta1 secretion, and shifted apoptosis markers (Bcl-2/Bax up, cleaved caspase-3/PARP down) in dermal papilla cells.
Same single in-vitro study; molecular/cell-culture endpoints only, no clinical outcome.
PubMed: Pyo 2007 (PMID 17703734) ↗A 2021 randomized controlled trial showed 0.05% AHK-Cu beat 5% minoxidil (22.7 vs 18.3 hairs/cm2); '47% DPC proliferation'; Seoul/Yonsei/King's College studies.
NOT VERIFIED, appears only on vendor/affiliate pages with no authors, journal volume, DOI or PMID; absent from PubMed and ClinicalTrials.gov. Treated as fabricated marketing content and given no evidentiary weight.
PubMed search for any AHK-Cu human trial (no clinical trial returned) ↗AHK-Cu is well tolerated topically with minimal systemic absorption and no documented serious adverse events.
Consistent across vendor/educational pages and plausible for a low-dose topical peptide, but there is NO published safety trial; rests on absence of reports plus general copper-peptide tolerability, not formal data.
PubMed: copper peptide topical safety / GHK-Cu (background class data) ↗Mechanism
How it's assumed to work
Assumed (not validated in humans). Proposed: the copper-bound Ala-His-Lys tripeptide acts on dermal papilla cells to promote proliferation and suppress apoptosis, raises VEGF to improve perifollicular blood supply, and lowers TGF-beta1 (a regression/catagen signal), collectively favoring a longer anagen (growth) phase. Copper-peptide class effects (lysyl oxidase activation, matrix/collagen remodeling) are also invoked. All inferred from one cell/tissue study.
Dosing & handling
What users and clinicians report
No established human dose. In cosmetic scalp serums AHK-Cu is typically formulated around 0.05% (often combined with GHK-Cu at higher percentages, e.g. serums marketed as '10% GHK-Cu / 5% AHK-Cu'), applied topically to the scalp once or twice daily and left on. The 2007 lab data found the active window at very low molar concentrations (10^-12 to 10^-9 M) with inhibition at higher concentrations, a caution that higher topical strengths are not necessarily better.
Reported from product labels and user practice, NOT prescribed or clinically validated. Cosmetic peptide serums are unregulated for actual content and stability; labeled percentages may not reflect delivered, intact peptide. Patch test first. There is no evidence-based dose, frequency, or duration for AHK-Cu in humans.
Timing & food
Applied topically to a clean, dry scalp, typically once or twice daily and left on (leave-in). Users commonly separate it from direct vitamin C / strong acid application to avoid destabilizing the copper complex, and may apply before or after (not simultaneously with) other actives. Food/systemic timing is irrelevant for a topical. No evidence-based timing exists; these are practical conventions.
Half-life
Not characterized in humans. As a topical tripeptide there is no meaningful systemic half-life reported; free peptides are generally short-lived to enzymatic cleavage, and the copper complex is intended for local skin/follicle activity rather than circulation. No pharmacokinetic data exist.
Reconstitution sensitivity
Most consumer use is a pre-formulated aqueous serum requiring no reconstitution. For raw powder, copper peptides are water-soluble and reconstituted in sterile/bacteriostatic water or incorporated into a cosmetic base; they are sensitive to oxidation, pH extremes, and incompatible with strong actives (e.g. high-dose vitamin C, certain acids) that can disrupt copper chelation. Keep cool and dark; the intact blue copper complex is the active form.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Low and largely derivative. There is a steady stream of marketing content, but genuine independent user discussion of AHK-Cu specifically is thin, far smaller than for minoxidil, finasteride, or even GHK-Cu. Most mentions are vendor product copy or appear as a secondary ingredient in GHK-Cu serum reviews.
Consistency
Mixed and muddled. Where users do report, outcomes range from 'some new hairs / less shedding' to 'no visible change,' often with the new hairs described as fine, dry, or fragile. Reports rarely isolate AHK-Cu from co-used treatments, and many conflate it with GHK-Cu, so the 'signal' is internally inconsistent and hard to attribute.
Source credibility
Low. A large share of positive claims originate from sellers, affiliate blogs, and product pages (heavily discounted as biased), several of which recycle the same unverifiable statistics. Independent, treatment-isolated, photo-documented accounts specific to AHK-Cu are scarce. Credibility is further eroded by widespread AHK-Cu/GHK-Cu conflation.
- Genuine AHK-Cu-specific chatter is sparse; it is usually discussed as a minor add-in to GHK-Cu copper-peptide serums, and many users conflate the two peptides.
- Among those who report results, sentiment is mixed-to-cautiously-positive: some describe modest new growth or reduced shedding after weeks-to-months, frequently noting the new hairs are fine, dry, or split easily.
- Skeptics question bioavailability and whether a topical peptide penetrates enough to matter, and point out results are inseparable from concurrent minoxidil/finasteride/microneedling.
- A recurring theme is reliance on vendor-supplied 'studies' and stats that users cannot independently verify, fueling doubt about marketing claims even among those willing to try it.
Placebo risk, High
Endpoints are overwhelmingly subjective and self-assessed (perceived thickness, shedding, hairline 'fuzz') rather than blinded standardized counts, and they are gathered in uncontrolled settings. Androgenetic alopecia naturally waxes and wanes, regimen adoption coincides with renewed grooming attention, and AHK-Cu is nearly always stacked with proven agents, a strong recipe for expectancy and misattribution effects.
Risk panel
What could go wrong
Adverse events
No published controlled safety data. Reported real-world issues are mild and typical of topicals: transient scalp redness, itching, dryness or stinging at the application site, and possible contact sensitization to copper or the peptide. Vendor pages cite roughly 2-4% mild irritation but this is not from a peer-reviewed trial.
Theoretical concerns
Copper is bioactive: chronic or high-dose topical loading, broken/abraded scalp, or pairing with microneedling could raise local copper exposure beyond what the single low-concentration study supports, and that study itself showed higher concentrations INHIBITED follicle growth, so 'more is better' dosing could be counterproductive. Long-term effects of daily scalp application are entirely unstudied.
Contraindications
Avoid in Wilson disease, Menkes disease, or any copper-metabolism disorder, and in known copper/peptide allergy. Do not combine topical copper peptides with unnecessary oral copper supplementation. Caution with broken skin or aggressive concurrent microneedling. Pregnancy/breastfeeding: untested, avoid by default.
Honest unknowns
Whether it does anything measurable on a living human scalp; the right concentration/vehicle for skin penetration; durability and whether gains (if any) reverse on stopping; interaction with minoxidil/finasteride beyond additive marketing claims; cumulative copper deposition with years of use; product-to-product variability and actual peptide content in unregulated cosmetic serums.
Confound watch
Almost no one uses AHK-Cu alone. It is typically one ingredient in serums that also contain GHK-Cu, and users commonly run it alongside minoxidil, finasteride, microneedling, ketoconazole, or supplements, any of which can drive results. Androgenetic alopecia also naturally fluctuates (seasonal shedding, stress), and outcomes are usually self-judged from mirror/photos. Attribution to AHK-Cu specifically is very weak. Community reports also routinely conflate AHK-Cu with GHK-Cu.
History
Discovery → first use → status
- 2007Pyo et al. publish the foundational and still-only primary study (Arch Pharm Res): AHK-Cu stimulates human hair-follicle elongation ex vivo and dermal papilla cell proliferation in vitro, with a narrow effective dose window.
- ~2010sAHK-Cu enters cosmetic supply chains as 'Copper Tripeptide-3,' marketed as a hair-targeted complement to GHK-Cu and blended into over-the-counter scalp serums.
- 2020sProliferation of vendor 'research summaries' citing a 2021 vs-minoxidil RCT and other university studies, none of which are findable in PubMed or ClinicalTrials.gov.
- June 2026Still no registered or published controlled human trial of AHK-Cu for hair growth; evidence base remains the single 2007 lab study.
Verification
The COA standard, applied
Primary evidence verified to a single resolvable source: Pyo HK et al., 'The effect of tripeptide-copper complex on human hair growth in vitro,' Arch Pharm Res 2007 (PMID 17703734), confirmed in vitro + ex vivo with no human in vivo arm. No AHK-Cu human trial found on PubMed; no ClinicalTrials.gov registration located. The frequently cited '2021 vs-minoxidil RCT' and assorted university studies were traced to vendor/affiliate pages carrying no authors, journal, DOI or PMID and are judged fabricated; they were excluded from grading.
The full verification standard →Sources
Where this comes from
- PubMed. Pyo 2007, tripeptide-copper complex on human hair growth in vitro (PMID 17703734, the only primary study) ↗· Foundational and sole primary research; in vitro + ex vivo (explanted follicles + cultured dermal papilla cells), no human in vivo arm.
- PubMed, search for any AHK-Cu human clinical trial for hair ↗· Returns no controlled human trial of AHK-Cu for hair growth, confirming the evidence gap.
- PubMed. AHK-Cu / copper tripeptide dermal papilla mechanism ↗· Mechanistic (VEGF up, TGF-beta1 down, anti-apoptotic) findings trace back to the single 2007 in-vitro study.
- PubMed, copper tripeptide topical skin safety (class background) ↗· Used only as background for general copper-peptide tolerability; no AHK-Cu-specific safety trial exists.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.